Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Lixte Biotechnology Holdings, Inc. (LIXT : NSDQ)
 
 • Company Description   
Lixte Biotechnology Holdings Inc. is a drug discovery company which uses biomarker technology to identify enzyme targets associated with serious common diseases. The company's product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers. Lixte Biotechnology Holdings Inc. is based in NY.

Number of Employees: 4

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.82 Daily Weekly Monthly
20 Day Moving Average: 1,363,940 shares
Shares Outstanding: 16.65 (millions)
Market Capitalization: $13.70 (millions)
Beta: -1.22
52 Week High: $4.12
52 Week Low: $0.77
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -31.43% -22.77%
12 Week -39.50% -33.48%
Year To Date -30.86% -15.52%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
680 EAST COLORADO BOULEVARD SUITE 180
-
PASADENA,CA 91101
USA
ph: 631-830-7092
fax: 631-982-5050
info@lixte.com http://www.lixte.com
 
 • General Corporate Information   
Officers
John S. Kovach - President and Chief Executive Officer
Robert N. Weingarten - Vice President and Chief Financial Officer
Philip F. Palmedo - Director
Stephen J. Forman - Director
Gil N Schwartzberg - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 539319202
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/09/22
Share - Related Items
Shares Outstanding: 16.65
Most Recent Split Date: (:1)
Beta: -1.22
Market Capitalization: $13.70 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/09/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 14.29%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -369.68
12/31/21 - -236.51
09/30/21 - -193.29
ROA
03/31/22 - -116.87
12/31/21 - -101.32
09/30/21 - -84.00
Current Ratio
03/31/22 - 6.37
12/31/21 - 16.81
09/30/21 - 24.35
Quick Ratio
03/31/22 - 6.37
12/31/21 - 16.81
09/30/21 - 24.35
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 0.00
12/31/21 - 0.09
09/30/21 - 0.19
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©